deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 0.67 [0.51; 0.89], 1 RCT, I2=0% conclusive
unassessable degree of certainty